



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q4
2023

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO
ANDREAS LÖSLER, CFO

March 1, 2024

DISCLAIMER




CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q4 2023

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up



HIGHLIGHTS

Developments bucking the chemical industry trend



Strong progress in development towards Specialty Chemical



Adjusted guidance 2023 achieved with EBITDA increase to 81.4 m€ and sales of 540.6 m€



Capacity increase of Creapure® supported strong growth in Specialty Chemicals; further growth capex scheduled



Strong operating cash flow 72.7 m€
NWC reduced



CSRD-based report installed
supply chain law implemented
Climate roadmap on track



Outlook 2024 with further growth in sales and EBITDA; Specialty Chemicals as growth driver

EXECUTIVE TEAM

Alzchem Group AG



DR. GEORG WEICHSELBAUMER

CSO

WITH ALZCHEM SINCE 2012

AREAS OF RESPONSIBILITY

Marketing, Sales, Innovation
management & process development,
R&D, product safety/approval

ANDREAS NIEDERMAIER

CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY

Corporate strategy, ESG,
risk management, legal/patents &
trademarks, supply chain management

KLAUS ENGLMAIER

COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY

Production, engineering, environmental
protection/safety/health/quality, technology

ANDREAS LÖSLER

CFO

WITH ALZCHEM SINCE 2022

AREAS OF RESPONSIBILITY

Finance & Controlling, Investor
Relations & Communications,
Human Resources, Insurance,
Information Technology

AGENDA – ANALYST PRESENTATION Q4 2023

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)


Successfully increased profitability




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	- 11.3%	- 21.1%
Price	- 3.4%	+ 5.9%
Currency	- 0.7%	- 0.3%

COMMENTS

- The decline in sales is mainly due to volume effects and elimination of low-margin business
- EBITDA with significant growth up to 9.5m EUR (+91.3%)
- Energy-intensive products with necessary price and production volume adjustments led to improved EBITDA
- Energy cost remain at a high level compared to periods before Ukraine war
- Products face strong competition from Asian competitors and Russian fertilizers with compete different cost structure
- Pricing strategy and decision not to compete with Asian low-price competitors led to an increased EBITDA



CREAMINO

Dormex[®]

Bioselect[®]

DYHARD[®]

Creapure[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)


Specialty Chemicals continued to be the growth driver of Alzchem



SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q4	DELTA 01 - 12
Volume	+11.6%	- 1.1%
Price	+ 13.8%	+ 12.7%
Currency	- 1.8%	- 0.7%

COMMENTS

- Strong volume increases in Q4 2023 in combination with price increases led to sales increase of 11%
- Sales in Human and Animal Nutrition as well as in Defense sector mainly contributed to the sales growth
- Additional capacity expansions in Creapure® plant completed in 2023, to meet the continuing increase in demand
- Custom Manufacturing and Bioselect® were below prior year; affected by the economic downturn in the chemical industry and destocking from customers.
- Higher portion of growth products within this segment led to almost 40% EBITDA increase (+ 20.3 M€) and an EBITDA margin of almost 23% (after 18,4% in prior year)
- Segment is the key driver for Alzchem's transformation into a Specialty Chemical company



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Segment developed as planned




SALES




EBITDA



SALES



EBITDA



COMMENTS

- 2023 sales are ~ 9 % above previous year's level based on pass-through of cost increases in pricing and higher grid fees in energy supply services
- Costs for internal technical supply and network costs that cannot be passed on to customers led to a decline in EBITDA

FINANCIAL OVERVIEW

Sustained growth in profitability



Alzchem Group	Q4 2022	Q4 2023	yoy %	2022 1 - 12	2023 1 - 12	yoy %
SALES (in M€)	133.2	142.8	+7.2%	542.2	540.6	-0.3%
EBITDA (in M€)	14.4	25.0	+73.8%	61.4	81.4	+32.6%
EBITDA margin (in %)	10.8%	17.5%	+6.7 pp	11.3%	15.1%	+3.8 pp
Earnings per Share (in €)	0.67	1.09	+62.5%	2.96	3.40	+14.9%

- Sales in 2023 slightly lower than previous year (-0.3%) in line with adjusted guidance. Segment Specialty Chemicals supports group growth while volume reductions led to a sales decline in Basics & Intermediates.
- Higher sales portion of Specialty Chemicals is followed by a strong EBITDA increase (+20.0 M€) and materially improved EBITDA margin up to 15.1 %.
- Energy and raw material costs are still high but without major jumps as last year; logistics are more predictable again – both developments led to a more stable pricing strategy
- Interest rate development has impacted net result but strong EBITDA development drove increase in earnings per share

SALES ANALYSIS


SALES ANALYSIS	DELTA Q4	DELTA 01 - 12
Volume	2,0%	-9,2%
Price	6,5%	9,4%
Currency	-1,3%	-0,5%

BALANCE SHEET (in M€)


Working capital reduction and increase in equity ratio



ASSETS



LIABILITIES




- Slight increase in total assets compared to last year with slight opposing effects from development of current and non-current assets
- Fixed assets are slightly below prior year resulting from lower capex compared to previous period; deferred tax assets grew due to increase in pension obligations
- Working capital optimization project successfully led to reduction in inventories; slightly lower raw material prices also contributed to the decrease
- High sales in Q4/2023 and factoring decrease results in growth in trade receivables; no changes in payment behavior from customer's side

- Significant improvement in group equity ratio to 38.5% (31/12/2022: 34.5%)
- Annual result positively influenced equity with 34.8 M€; opposite effects due to development of interests for pension provisions of 6 M€ (after deduction of deferred taxes), as well as dividend payment of 10.7 M€ in May 2023
- As interest rates declined from 3.7% to 3.2% in December 2023, pension obligations have increased accordingly
- Repayment of non-current bank liabilities as scheduled; working capital financing lines completely repaid (56.4 M€)

CASHFLOW (in M€)

High increase in free cashflow was used to reduce debts



- Operating cashflow turned positive again with an increase of 76.9 M€ compared to last year – mainly impacted by successful reduction of working capital and positive operating result
- Cashflow from investing activity slowed down compared to 2022 (-8.0 M€) due to a cautious investment policy in 2023; investing in capacity expansions of the Creapure®-plant and renewal of the grid operations nevertheless were pushed forward
- As a result, free cashflow increased by 84.9 M€ compared to prior year

- Financing cashflow was impacted from opposing effects:
 - Complete repayment of short-term financing lines (56.4 M€) and scheduled reduction of long-term loans and lease liabilities (12.0 M€)
 - Refinancing of working capital lines (30.0 M€)
 - Dividend payment (10.7 M€)
- Very stable financing situation

IMPLEMENTING OPERATING TARGETS 2024

Focus on the key growth drivers and sustainability



IMPROVEMENT

- Pass on raw material price increases to the market
- Flexibilization of production and processes
- Volume growth & full capacity utilization




GROWTH

- Increase the availability of Creamino® worldwide
- Examine growth opportunities in USA
- Accompany market growth of Creapure® through additional CAPEX
- Embed Eminex® on the certificate market



SUSTAINABILITY

- Vision 0 accidents and 0 waste
- Realization of climate roadmap
- Implement EU Taxonomy Regulation and CSRD in an audit-ready manner
- Enjoyment of work – realization of the feedback from the employee survey




OUTLOOK 2024 (in M€)


Further growth in sales, EBITDA and EBITDA-margin expected



SALES



EBITDA



COMMENTS

- The Outlook is based on following assumptions:
 - ✓ No occurrence of a global recession
 - ✓ Price development of costs for raw materials, logistics and electricity stable at the level of the last quarter of 2023
 - ✓ Existing product registrations remain in place, new registrations applied for will be granted
 - ✓ Availability of raw materials and logistics
 - ✓ Ukraine war does not deliver further interruptions
- Products in Specialty chemicals continue to be the growth driver of Alzchem in sales and EBITDA
 - ✓ Creapure®, Creamino® and Nitroguanidin will support growth in volume, sales and EBITDA
- Sales in the Basics & Intermediates segment decline slightly, mainly due to price formulas
- Sales shift into Specialty Chemicals will also contribute to an increase in overall group EBITDA-margin – up to 15,8% from

FINANCIAL CALENDAR

Upcoming dates*



APR 4	2024	Baader Bank Roadshow Paris
APR 30	2024	Quarterly Statement 1 st Quarter 2024
MAY 7	2024	Annual General Meeting
MAY 13-15	2024	Frühjahrskonferenz
AUG 1	2024	Quarterly Statement 2 nd Quarter 2024
SEP 25	2024	Berenberg and Goldman Sachs German Corporate Conference
SEP	2024	Baader Investment Conference
NOV 7	2024	Quarterly Statement 3 th Quarter 2024
NOV 13	2024	Münchner Kapitalmarkt Konferenz
NOV 25-26	2024	Deutsches Eigenkapitalforum

*subject to change

FEEDBACK

We appreciate your feedback



Were your expectations met?

Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

[Link](#)

QR-Code



**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q4 2023

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




ALZCHEM GROUP (IN T€)	31.12.2022	31.12.2023	Deviation	
Intangible assets	2,954	3,664	710	24.0%
Tangible assets	181,526	177,281	-4,246	-2.3%
Investment properties				
Right of use (assets)	6,250	4,855	-1,395	-22.3%
Investments accounted for using the equity method				
Financial assets	6	6	0	0.0%
Trade receivables				
Other receivables	1,531	1,371	-161	-10.5%
<i>there of Deferred tax assets for pensions provisions</i>				
Deferred tax assets	15,956	20,921	4,965	31.1%
SUM NON-CURRENT ASSETS	208,223	208,096	-127	-0.1%
Inventories	122,404	107,479	-14,925	-12.2%
Trade receivables	55,712	75,212	19,500	35.0%
Financial assets	5,228	0	-5,228	-100.0%
Other receivables	19,743	19,239	-504	-2.6%
Income tax receivables	2,307	2,769	461	20.0%
Cash and cash equivalents	9,243	11,883	2,639	28.6%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	214,638	216,581	1,944	0.9%
SUM ASSETS	422,860	424,677	1,817	0.4%

ALZCHEM GROUP (IN T€)	31.12.2022	31.12.2023	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	121,044	144,979	23,935	19.8%
Other comprehensive income	-15,316	-21,639	-6,323	41.3%
Own shares	-1,009		1,009	-100.0%
SHARE TO THE SHAREHOLDERS	144,012	161,625	17,613	12.2%
Non-controlling interests	1,934	1,934		
SUM EQUITY	145,947	163,559	17,613	12.1%
Provisions for pensions	90,141	100,294	10,153	11.3%
Other provisions	17,011	19,691	2,680	15.8%
Loans	27,498	48,665	21,167	77.0%
Finance lease liabilities	4,622	3,377	-1,245	-26.9%
Trade liabilities				
Other liabilities	171	171		
Deferred tax liabilities	5,365	6,289	924	17.2%
SUM NON-CURRENT LIABILITIES	144,808	178,487	33,679	23.3%
Other provisions	1,944	3,537	1,593	82.0%
Loans	66,408	8,833	-57,575	-86.7%
Finance lease liabilities	1,707	1,613	-94	-5.5%
Finance liabilities				
Trade liabilities	37,386	31,554	-5,833	-15.6%
Other liabilities	23,060	28,930	5,870	25.5%
Income tax liabilities	1,602	8,164	6,563	409.8%
SUM CURRENT LIABILITIES	132,106	82,631	-49,475	-37.5%
Sum EQUITY AND LIABILITIES	422,860	424,677	1,817	0.4%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Decrease in interest rates from 3.7% to 3.2% and minimal changes in experience assumptions leading to a net pension increase of 8.3 M€
- Pension trend (2.25%) and salary trend (3.00%) remain unchanged compared to December 31st, 2022
- Pension payments develop as expected with 1.9 M€ - pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Deviation (Q4)	
Revenue	129,395	140,435	139,193	133,200	150,432	126,599	120,824	142,794	9,594	7%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	14,144	14,467	-1,959	-4,459	916	9,105	147	-13,972	-9,513	213%
Other income	4,070	5,736	5,955	8,416	5,574	1,906	3,104	3,274	-5,142	-61%
Raw materials and consumables used	-73,537	-74,027	-75,308	-66,006	-76,159	-62,374	-48,544	-38,067	27,939	-42%
Employee benefits expense	-34,000	-36,287	-31,316	-35,537	-35,262	-36,012	-34,678	-39,684	-4,148	12%
Other expense	-23,003	-32,517	-24,418	-21,198	-26,583	-21,352	-21,317	-29,295	-8,097	38%
EBITDA	17,070	17,807	12,149	14,416	18,917	17,872	19,534	25,049	10,633	74%
Depreciation expense	-6,305	-6,299	-6,324	-6,616	-6,320	-6,335	-6,574	-6,670	-54	1%
Impairment										
EBIT	10,765	11,508	5,825	7,800	12,598	11,537	12,960	18,379	10,579	136%
Investment income										
Other interest and similar income	1,181	2,393	2,466	2,380	49	106	661	-434	-2,814	-118%
Other interest and similar expense	-603	-643	-753	-1,037	-1,882	-1,661	-1,586	-2,537	-1,500	145%
Financial result	578	1,750	1,713	1,343	-1,832	-1,555	-925	-2,971	-4,314	-321%
Result from associates										
Result from ordinary business	11,343	13,258	7,538	9,143	10,765	9,982	12,035	15,407	6,264	69%
Taxes on income and profit	-3,603	-3,629	-1,559	-2,269	-3,055	-2,742	-3,379	-4,222	-1,953	86%
<i>thereof income tax</i>	-2,520	-2,094	-842	562	-2,946	-2,716	-3,015	-6,431	-6,993	<-1.000
<i>thereof change from deferred taxes</i>	-1,082	-1,535	-717	-2,831	-109	-26	-364	2,209	5,040	-178%
Annual result	7,740	9,630	5,979	6,874	7,710	7,240	8,656	11,185	4,311	63%
<i>thereof minority interests</i>	43	43	43	43	43	43	43	43		
<i>thereof shares held by shareholders</i>	7,698	9,587	5,936	6,831	7,667	7,197	8,613	11,142	4,311	63%
Result per share in EUR	0.76 €	0.95 €	0.59 €	0.67 €	0.76 €	0.71 €	0.85 €	1.09 €		

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

Revenue	
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	
Other income	
Raw materials and consumables used	
Employee benefits expense	
Other expense	
EBITDA	
Depreciation expense	
Impairment	
EBIT	
Investment income	
Other interest and similar income	
Other interest and similar expense	
Financial result	
Result from associates	
Result from ordinary business	
Taxes on income and profit	
<i>thereof income tax</i>	
<i>thereof change from deferred taxes</i>	
Annual result	
<i>thereof minority interests</i>	
<i>thereof shares held by shareholders</i>	
Result per share in EUR	

Q4 2022	Q4 2023	Deviation (QoQ)	
133,200	142,794	9,594	7.2%
-4,459	-13,972	-9,513	213.4%
8,416	3,274	-5,142	-61.1%
-66,006	-38,067	27,939	-42.3%
-35,537	-39,684	-4,148	11.7%
-21,198	-29,295	-8,097	38.2%
14,416	25,049	10,633	73.8%
-6,616	-6,670	-54	0.8%
0	0	0	
7,800	18,379	10,579	135.6%
0	0	0	
2,380	-434	-2,814	-118.2%
-1,037	-2,537	-1,500	144.7%
1,343	-2,971	-4,314	-321.2%
0	0	0	
9,143	15,407	6,264	68.5%
-2,269	-4,222	-1,953	86.1%
562	-6,431	-6,993	< -1.000%
-2,831	2,209	5,040	-178.0%
6,874	11,185	4,311	62.7%
43	43	0	0.0%
6,831	11,142	4,311	63.1%
0.67 €	1.09 €	0	62.5%

YTD Dez.2022	YTD Dez.2023	Deviation (YoY)	
542,223	540,649	-1,574	-0.3%
22,193	-3,804	-25,997	-117.1%
24,177	13,857	-10,320	-42.7%
-288,877	-225,145	63,732	-22.1%
-137,139	-145,637	-8,498	6.2%
-101,136	-98,548	2,588	-2.6%
61,441	81,372	19,931	32.4%
-25,543	-25,899	-356	1.4%
0	0	0	
35,898	55,473	19,575	54.5%
0	0	0	
8,421	382	-8,039	-95.5%
-3,036	-7,666	-4,629	152.5%
5,385	-7,284	-12,669	-235.3%
0	0	0	
41,282	48,189	6,907	16.7%
-11,059	-13,398	-2,339	21.1%
-4,895	-15,108	-10,214	208.7%
-6,165	1,710	7,875	-127.7%
30,223	34,791	4,568	15.1%
171	171	0	0.0%
30,052	34,620	4,568	15.2%
2.96 €	3.40 €	0	14.9%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

	Q4 2022	Q4 2023	1 - 12 2022	1 - 12 2023
Consolidated earnings before taxes	9.143	15.407	41.282	48.189
Depreciation on fixed and intangible assets	6.616	6.670	25.543	25.899
Decrease in pension provisions	-398	-482	-1.651	-1.889
Loss (+) / Profit (-) from the sale of non-current assets	-7		-65	-9
Other non-cash income (-) and expenses (+)	89	9.989	2.891	13.740
Financial result	-1.343	2.971	-5.385	7.284
Interests & Taxes	-2.452	-2.430	-8.647	-11.944
Increase (+) / Decrease (-) Net Working Capital	-1.789	-4.160	-58.208	-8.600
Cashflow from ongoing operations (Net cash flow)	9.859	27.966	-4.240	72.671
Cash outflows for investments in fixed assets	-6.325	-6.326	-29.068	-20.556
Cash inflows from the sale of fixed assets	7	0	68	9
Cash inflows from the disposal of investments	5		489	
Cashflow from investing activity	-6.313	-6.326	-28.511	-20.548
Free cashflow	3.546	21.640	-32.751	52.123
Deposits (+) / Repayment (-) bank loans long-term				30.000
Repayment of bank loans long-term	-2.514	-3.293	-10.490	-10.055
Deposits (+) / Repayment (-) from short-term financing lines	-604	-22.489	56.353	-56.353
Dividend payments			-10.136	-10.685
Payment of reduction in leasing liabilities	-498	-571	-1.909	-1.902
Payments for the acquisition of own shares (incl. transaction costs)				
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	-3.616	-26.353	33.647	-49.165
Net increase / decrease in cash and cash equivalents	-70	-4.713	896	2.957

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES


SALES	2021				2022				2023				Deviation PY (Q4)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%
Basics & Intermediates	41.070	45.178	42.465	47.561	57.441	57.927	59.557	52.614	57.337	46.038	44.271	44.538	-8.076	-15%
Specialty Chemicals	56.775	59.330	47.116	57.279	65.279	76.214	72.967	73.902	85.783	73.172	69.545	91.302	17.399	24%
Other and Holding	6.477	6.492	6.339	6.212	6.675	6.294	6.670	6.684	7.312	7.389	7.007	6.955	271	4%
Group Consolidation														
Alzchem Group	104.321	111.000	95.920	111.052	129.395	140.435	139.193	133.200	150.432	126.599	120.824	142.794	9.594	7%

EBITDA

EBITDA	2021				2022				2023				Deviation PY (Q4)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%
Basics & Intermediates	2.791	3.826	3.118	1.250	2.841	853	-2.621	3.910	2.780	2.410	1.065	3.275	-635	-16%
Specialty Chemicals	13.947	14.801	10.096	11.820	14.267	16.322	14.637	7.789	16.019	14.936	18.541	23.747	15.958	205%
Other and Holding	435	-43	512	502	-139	830	1.038	230	475	438	721	-1.171	-1.401	-610%
Group Consolidation	-451	409	112	-1.079	103	-200	-905	2.487	-357	88	-793	-802	-3.289	-132%
Alzchem Group	16.722	18.993	13.838	12.493	17.072	17.805	12.149	14.416	18.917	17.872	19.534	25.049	10.633	74%


ALZCHEM GROUP LOCATIONS

Production sites and sales companies



“VERBUND” – FULLY INTEGRATED BUSINESS MODEL

Benefits of the “Verbund” system approach



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS



POPULATION
GROWTH



LONGER LIFE
EXPECTANCY



CLIMATE
CHANGE



SUSTAINABILITY

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries







MAIN PRODUCTS		DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A nutritional additive for poultry and pigs	Feed additive
	Creapure®	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis®	Creatine for health and food applications	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for explosives and agrochemical products	Agriculture, Automotive, Defense

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	 NITRALZ [®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Eminex [®]	Reduction of methane emissions during storage of manure	Agriculture
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Aramark, VIACTIV)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		


KEY SHARE DATA

Share Details as of February 28, 2024



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 25.80
MARKET CAPITALIZATION	EUR 263 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
DESIGNATED SPONSOR	Baader Bank AG ODDO BHF Corporate & Markets AG

SHAREHOLDER STRUCTURE



As of April 2023. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the “Guide to the DAX Equity Indices”.